Keywords: Biomarkers; CDK inhibitors; Complete response; Metastatic breast cancer; Palbociclib;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Antiangiogenic agents; Breast cancer; Comprehensive; OmniseqSM; Palbociclib;
Keywords: Advanced breast cancer; Palbociclib; Letrozole; Cost-utility; Cost-effectiveness;
Keywords: Endocrine resistance; Breast cancer; Fulvestrant; Palbociclib; Everolimus; Mechanism of resistance;
Keywords: Phase I; Palbociclib; Cetuximab; Head and neck cancer; Squamous cell carcinoma
Keywords: CDKs; Anticancer; Palbociclib; Synthesis
Keywords: Abemaciclib; CDK 4/6 inhibitors; Hormone receptor-positive breast cancer; Palbociclib; Ribociclib;
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer
Keywords: Hormone receptor-positive metastatic breast cancer; Endocrine therapy; Endocrine resistant; Palbociclib; Heavily pretreated;
Palbociclib-Induced Thrombotic Microangiopathy in Metastatic Breast Cancer Patient Surviving for 18 Years: Case Report and Review of the Literature
Keywords: Anemia; Drug-induced TMA; Palbociclib; Thrombocytopenia; Thrombotic microangiopathy (TMA);
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
Keywords: Palbociclib; Fulvestrant; Advanced breast cancer; HR+/HER2-; Long-term response;
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Keywords: Advanced breast cancer; Age; HR-positive; Endocrine treatment; HER2-negative; Tumour; Letrozole; Fulvestrant; Palbociclib;
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response
Keywords: Palbociclib; HCC; CCA; Radiosensitivity; PP5; ATM;
In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites
Keywords: Palbociclib; UHPLC/Q-TOF/MS/MS; Metabolite identification; Characterization; In silico studies;
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Keywords: CDK4; cyclin-dependent kinase 4; RNAi; RNA interference; siRNA; small interfering RNA; Rb; retinoblastoma; TMA; tissues microarray; Osteosarcoma; Cyclin-dependent kinase 4; Palbociclib; Rb; Cell cycle;
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Keywords: Metastatic breast cancer; Estrogen receptor-positive/HER2â breast cancer; Unmet needs; Palbociclib;
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib
Keywords: Ribociclib; Palbociclib; Neutropenia; Infection;
Palbociclib-induced autophagy and senescence in gastric cancer cells
Keywords: Autophagy; Senescence; Palbociclib; Gastric cancer;
CDK4/6 inhibitors in HER2-positive breast cancer
Keywords: Breast cancer; Advanced breast cancer; HER2 positive BC; Cyclin-dependent kinases (CDK); Palbociclib; Ribociclib; Abemaciclib;
CDK4/6 inhibition in early and metastatic breast cancer: A review
Keywords: Breast cancer; Palbociclib; Ribociclib; Abemaciclib; Cyclin-dependent kinase 4/6; CDK4/6 inhibition;
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
Keywords: Palbociclib; Ribociclib; Abemaciclib; CDK 4; CDK 6; CDK 4 inhibitors; CDK 6 inhibitors; CDK4/6 inhibitors; retinoblastoma; retinoblastoma protein; me-too cancer therapies; FDA approvals;
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Keywords: cyclin dependent kinase; CDK4/6 inhibitor; cell cycle; breast cancer; palbociclib;
Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study
Keywords: Cell cycle; Cyclin-dependent kinases; Germ cell tumor; Palbociclib; Retinoblastoma protein;
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
Keywords: urinary bladder neoplasms; retinoblastoma; cyclin-dependent kinase inhibitor proteins; palbociclib; biological markersBLCA, bladder cancer; CAM, chorioallantoic membrane; CDK, cyclin dependent kinase; CI, combination index; CMV, cytomegalovirus; IC50, 50%
Update on rational targeted therapy in AML
Keywords: High-risk AML; IDH; BET; HDAC inhibitors; LSD1; DOT1L; Flavopiridol; Palbociclib; Volasertib; Wee1; Idasanutlin; Aurora kinase; Rigosertib; Hedgehog; BH3-mimetic; Venetoclax; Pevonedistat; Tosedostat
A theoretical study of the structure and protonation of Palbociclib (PD 0332991)
Keywords: Palbociclib; Pyrido[2,3-d]pyrimidinone; Protonation; B3LYP/6-311++G(d,p); GIAO